Liarozole (R75251) dihydrochloride 是一种咪唑衍生物和具有口服活性的维甲酸 (RA) 代谢阻断剂(RAMBA)。Liarozole dihydrochloride 抑制细胞色素P450(CYP26) 依赖的维甲酸 4- 羟基化 (IC50=7 μM),导致组织 RA 水平增加。Liarozole dihydrochloride 具有抗肿瘤活性。
生物活性 | Liarozole (R75251) dihydrochloride is an imidazole derivative and orally activeretinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochromeP450(CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties[1][2][3]. |
IC50& Target | |
体外研究 (In Vitro) | Liarozole dihydrochloride (0.01~10 μM; 9 days; MCF-7 cells) inhibits cells proliferation[3]. Liarozole dihydrochloride (1 μM; 4 days; mesenchymal cells) completely inhibits chondrogenesis[4].
Cell Proliferation Assay[3] Cell Line: | MCF-7 cells | Concentration: | 0.01~10 μM | Incubation Time: | 9 days | Result: | Had an effect of 35% inhibition at 10 μM on cell proliferation. |
Cell Differentiation Assay[4] Cell Line: | Mesenchymal cells | Concentration: | 1 μM | Incubation Time: | 4 days | Result: | Completely inhibited chondrogenesis. |
|
体内研究 (In Vivo) | Liarozole dihydrochloride (5-20 mg/kg; p.o.) reverses the vaginal keratosis caused by estrogen stimulation[5]. Liarozole dihydrochloride (40 mg/kg; p.o.) reduces tumor burden substantially[6].
Animal Model: | Ovariectomized rats | Dosage: | 5~20 mg/kg | Administration: | P.o. | Result: | Reversed the vaginal keratosis caused by estrogen stimulation. |
Animal Model: | SCID mice | Dosage: | 40 mg/kg | Administration: | P.o. | Result: | Inhibited tumor growth and survival. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: H2O : ≥ 50 mg/mL(131.00 mM) DMSO : 50 mg/mL(131.00 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.6199 mL | 13.0996 mL | 26.1993 mL | 5 mM | 0.5240 mL | 2.6199 mL | 5.2399 mL | 10 mM | 0.2620 mL | 1.3100 mL | 2.6199 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 100 mg/mL (261.99 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.45 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.45 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.45 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|